Bibliographic information
GuidelineWHO guidelines on tuberculosis infection prevention and control: 2019 update
Year of Publication2019
Issuing InstitutionWHO
Recommendation
New
Levofloxacin or moxifloxacin should be included in the treatment of multidrug-resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB) patients on longer regimens.
Recommended in favor
Strong
Certainty of evidence
Moderate